2. Metabolic Enzyme/Protease
  3. β-glucuronidase
  4. 6-Keto-PGE1

6-Keto-PGE1  (Synonyms: 6-keto-Prostaglandin E1)

Cat. No.: HY-114986 Purity: 99.0%
COA
SDS
Handling Instructions Technical Support

6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1. 6-Keto-PGE1 inhibits adenosine diphosphate-induced platelet aggregation. 6-Keto-PGE1 reduces cardiac afterload, decreases the accumulation of plasma myocardial depressant factor (MDF), lowers arterial blood pressure, dilates vascular beds, inhibits the vasoconstrictive response of vascular smooth muscle, and increases pulmonary compliance. 6-Keto-PGE1 directly stabilizes isolated cat liver lysosomes and significantly reduces the release of β-glucuronidase and cathepsin D. 6-Keto-PGE1 prolongs the survival time of traumatized rats and exerts protective effects through hemodynamic and cytoprotective actions. 6-Keto-PGE1 reduces central airway resistance. 6-Keto-PGE1 can be used in studies related to traumatic shock.

For research use only. We do not sell to patients.

6-Keto-PGE1

6-Keto-PGE1 Chemical Structure

CAS No. : 67786-53-2

Size Price Stock Quantity
Solvent
1 mg (2.71 mM * 1 mL in Ethanol) In-stock

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

6-Keto-PGE1 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE 6-Keto-PGE1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

6-Keto-PGE1 (6-keto-Prostaglandin E1) is a biologically active derivative of PGE1. 6-Keto-PGE1 inhibits adenosine diphosphate-induced platelet aggregation. 6-Keto-PGE1 reduces cardiac afterload, decreases the accumulation of plasma myocardial depressant factor (MDF), lowers arterial blood pressure, dilates vascular beds, inhibits the vasoconstrictive response of vascular smooth muscle, and increases pulmonary compliance. 6-Keto-PGE1 directly stabilizes isolated cat liver lysosomes and significantly reduces the release of β-glucuronidase and cathepsin D. 6-Keto-PGE1 prolongs the survival time of traumatized rats and exerts protective effects through hemodynamic and cytoprotective actions. 6-Keto-PGE1 reduces central airway resistance. 6-Keto-PGE1 can be used in studies related to traumatic shock[1][2][3].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

6-Keto-PGE1 (1 μg/mL; 30 min) directly stabilizes isolated cat liver lysosomes, significantly reducing the release of β-glucuronidase and cathepsin D[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6-Keto-PGE1 Related Antibodies
In Vivo

6-Keto-PGE1 (250 ng/kg/min; i.v.; continuous infusion; starting 15 min after trauma for experiment duration) significantly prolongs survival time to 2.6 hours in rats with traumatic shock, while reducing plasma levels of cathepsin D and MDF and stabilizing mean arterial blood pressure[1].
6-Keto-PGE1 (250 ng/kg/min; i.v.; continuous infusion; 5 hours) produces a modest, sustained decrease in mean arterial blood pressure (23 mmHg total reduction at 5 hours) without altering heart rate in healthy sham-operated rats[1].
6-Keto-PGE1 (1 μg/min; i.a.; infusion) significantly reduces mesenteric perfusion pressure by ~27-31% and reversibly inhibits vasoconstrictor responses to sympathetic nerve stimulation, norepinephrine, and angiotensin II in the feline mesenteric vascular bed[2].
6-Keto-PGE1 (0.3-10 μg; i.v.; rapid injection) acts as a potent bronchodilator in 5-HT-induced bronchoconstricted cats, reducing central airway resistance 3-10 times more potently than PGI2, with minimal pulmonary vasomotor activity, and its effects are independent of cyclooxygenase pathway stimulation[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 210-250 g, traumatic shock induced by Noble-Collip drum trauma under sodium pentobarbital anesthesia)[1]
Dosage: 250 ng/kg/min
Administration: i.v.; continuous infusion; starting 15 min after trauma for experiment duration
Result: Prolonged mean survival time to 2.6 hours.
Inhibited trauma-induced increase in plasma cathepsin D activity, reducing it from ~14 units/mg protein to ~9 units/mg protein.
Reduced plasma MDF activity from ~58 units to ~30 units.
Increased mean arterial blood pressure to 108 mmHg at 0.5 hours and maintained this level for 2 hours in 7 out of 10 treated rats.
Animal Model: Sprague-Dawley (male, 210-250 g, sham-operated, no trauma)[1]
Dosage: 250 ng/kg/min
Administration: i.v.; continuous infusion; 5 hours
Result: Decreased mean arterial blood pressure by 15 mmHg 5 minutes after infusion start, followed by a 10 mmHg increase by 15 minutes.
Maintained a mean arterial blood pressure of 117 mmHg at 5 hours, down from an initial 140 mmHg.
Caused no significant changes in heart rate.
Animal Model: Domestic cats (adult, either sex, 1.9 to 4.3 kg)[2]
Dosage: 1 μg/min
Administration: i.a.; infusion
Result: Reduced mesenteric arterial perfusion pressure from a control of 105 mmHg to 76 mmHg at 1 minute, 73 mmHg at 3 minutes, 72 mmHg at 5 minutes, 77 mmHg at 10 minutes, and 76 mmHg at 30 minutes.
Returned perfusion pressure to baseline (105 mmHg) 30 minutes after infusion cessation.
Reduced vasoconstrictor responses to all tested doses of norepinephrine (0.3, 1, 3 μg i.a.), all tested frequencies of sympathetic nerve stimulation (1, 3, 10 cycles/sec), and all tested doses of angiotensin II (0.3, 1 μg i.a.) during infusion.
Restored all suppressed vasoconstrictor responses to control levels 30 minutes after infusion termination.
Animal Model: Mongrel cats (either sex, 2.0-4.5 kg)[3]
Dosage: 0.3 μg; 1.0 μg; 3.0 μg; 10.0 μg
Administration: i.v.; rapid injection
Result: Produced statistically significant reductions in central airway resistance (RL) and increases in dynamic lung compliance (Cdyn) and semi-static compliance (C'stat') compared to 5-HT-elevated tone controls.
Decreased RL from 38 cm H2O/L/sec to 35 cm H2O/L/sec, increased Cdyn from 4.0 mL/cm H2O to 4.5 mL/cm H2O, increased C'stat' from 3.2 mL/cm H2O to 3.5 mL/cm H2O, and caused no significant change in pulmonary arterial pressure (PPA) at 0.3 μg.
Decreased RL from 38 cm H2O/L/sec to 32 cm H2O/L/sec, increased Cdyn from 4.4 mL/cm H2O to 4.9 mL/cm H2O, increased C'stat' from 3.4 mL/cm H2O to 3.9 mL/cm H2O, and caused no significant change in PPA at 1.0 μg.
Decreased RL from 34 cm H2O/L/sec to 27 cm H2O/L/sec, increased Cdyn from 4.4 mL/cm H2O to 5.2 mL/cm H2O, increased C'stat' from 3.5 mL/cm H2O to 4.5 mL/cm H2O, and decreased PPA significantly from 25 mm Hg to 23 mm Hg at 3.0 μg.
Decreased RL from 32 cm H2O/L/sec to 22 cm H2O/L/sec (a 32% reduction from elevated tone, representing a 50% return to pre-5-HT control values), increased Cdyn from 5.3 mL/cm H2O to 6.2 mL/cm H2O, increased C'stat' from 4.1 mL/cm H2O to 5.1 mL/cm H2O, and caused no significant change in PPA at 10.0 μg.
Was 3-10 times more potent than PGI2 at reducing RL, and more potent than PGI2 at increasing Cdyn at lower doses.
Had a time to maximum response (tmax) ranging from 30 seconds to 42 seconds, which was significantly shorter than tmax for PGI2 at comparable potency doses.
Had a duration of response (t1/2) ranging from 52 seconds to 103 seconds, with no consistent difference compared to PGI2.
Showed airway and vascular responses unaltered by pretreatment with sodium meclofenamate.
Molecular Weight

368.46

Formula

C20H32O6
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

OC(CCCCC(C[C@@H]1[C@H]([C@@H](CC1=O)O)/C=C/[C@@H](O)CCCCC)=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Solution, -20°C, 2 years
Purity & Documentation

Purity: 99.0%

SDS (479 KB)

COA (252 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

6-Keto-PGE1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

6-Keto-PGE167786-53-26-keto-Prostaglandin E1β-glucuronidaseGUSBtraumatized ratscardiac afterloadtraumatic shockcathepsin Dcat liver lysosomes5-HT-induced bronchoconstricted catsfeline mesenteric vascular bedplatelet aggregationvascular smooth muscleInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
6-Keto-PGE1
Cat. No.:
HY-114986
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (479 KB) Français - FR (479 KB) Deutsch - DE (479 KB) Norwegian - NO (479 KB) Español - ES (479 KB) Swedish - SV (479 KB) Italian - IT (479 KB) Korean - KR (479 KB) Portuguese - PT (479 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.